Metafora^®–SR

– Reducing the risk or delaying the onset of type 2 diabetes mellitus in overweight adults with PTH* and/or PGN* and/or elevated HbA1C levels who have: a high risk of developing overt (manifest) type 2 diabetes mellitus (see Pharmacodynamics section); progressive carbohydrate metabolism disorders despite modification of an active lifestyle for 3 to 6 months.

Treatment with Metformin SR should be based on a risk assessment that includes appropriate glycaemic control measures and evidence of high cardiovascular risk. Lifestyle changes should be continued in parallel with the start of metformin, unless the patient is medically unable to make such changes: Impaired glucose tolerance; HGT: Impaired fasting glycaemia. – Treatment of type 2 diabetes mellitus in adults, especially in overweight patients, when dietary therapy and physical activity alone do not provide adequate glycaemic control. The medicine can be used as monotherapy or in combination with other oral antidiabetic agents, or in combination with insulin.